The GSP Neonatal 17α-OH-progesterone assay is intended for the quantitative determination of 17OHP in dried blood spot specimens as an aid in screening newborns for CAH.
Feature | Specification |
---|---|
Application | Newborn Screening |
The GSP Neonatal 17α-OH-progesterone assay is intended for the quantitative determination of 17OHP in dried blood spot specimens as an aid in screening newborns for CAH.
Congenital adrenal hyperplasia (CAH) is a genetic disorder and the most severe form of the disease can lead to a life threatening condition during the first weeks of life. The disease is caused by enzyme defects in steroid biosynthesis, the most frequent types being 21- and 11a-hydroxylase deficiency. These types represent 95% of CAH cases and in both, the 17a-OH progesterone (17OHP), a precursor of cortisol, is increased. The determination of 17OHP is thus a useful screening method for 95% of all CAH cases.
GSP Neonatal 17a-OH-progesterone assay:
The GSP Neonatal 17a-OH-progesterone assay is based on the competitive binding of europium-labeled 17OHP and 17OHP in the sample to 17OHP-specific antibodies. The fluorescence signal is inversely proportional to the analyte concentration in the sample.
All Revvity neonatal products may not be available in all countries.
Application |
Newborn Screening
|
---|---|
Brand |
GSP®
|
Detection Modality |
Time-Resolved Fluorescence (TRF)
|
Disorders |
Congenital Adrenal Hyperplasia (CAH)
|
Instrument Compatibility |
GSP
|
Quantity |
1152 tests
|
Sample Type |
Dried blood spots
|
Technology |
DELFIA
|
Unit Size |
1 kit
|
Are you looking for resources, click on the resource type to explore further.
We are here to answer your questions.